Related Experiment Video
Updated: Jun 19, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Interstitial granulomatous dermatitis in rheumatoid arthritis responsive to etanercept
Angelo Zoli1, Guido Massi, Michela Pinnelli
1Department of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy. angelo.zoli@rm.unicatt.it
Abstract:
Interstitial granulomatous dermatitis (IGD) is a rare dermatological condition presenting as erythematous plaques. It may be associated with drug-related adverse reactions and autoimmune diseases. Recent cases of IGD have been reported in rheumatoid arthritis (RA) patients treated with biologic agents. We report a case of RA patient with persistent erythematous plaques who did not respond to traditional disease-modifying anti-rheumatic drugs with a persistent skin condition of erythematous plaque eruptions. A biopsy showed a homogeneous inflammatory infiltrate in the deep dermis composed of large epithelioid histiocytes with occasional granulocytes, leading us to consider a diagnosis of IGD. The cutaneous lesions disappeared after a 3-month treatment with the tumour necrosis factor-alpha (TNF-alpha) inhibitor etanercept. Anti-TNF-alpha agents can antagonise the multiple effects of TNF-alpha on the immune system, effects that are required for the continued maintenance of granulomatous structure, and offer a therapeutic strategy in the treatment of IGD associated with arthritis.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Chronic Inflammation: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Hypersensitivity Reactions: Immune-Complex Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
